Compare · CBLL vs LIVN
CBLL vs LIVN
Side-by-side comparison of CeriBell Inc. (CBLL) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.32B, about 4.1x CBLL ($1.06B).
- Both names hit the wire about 2 times in the past 4 weeks.
- LIVN has more recent analyst coverage (21 ratings vs 8 for CBLL).
- Company
- CeriBell Inc.
- LivaNova PLC
- Price
- -
- -
- Market cap
- $1.06B
- $4.32B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- News (4w)
- 2
- 2
- Recent ratings
- 8
- 21
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest CBLL
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $119,145 worth of shares (4,887 units at $24.38) as part of a pre-agreed trading plan (SEC Form 4)
- Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
- President and CEO Chao Xingjuan sold $521,775 worth of shares (20,846 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 746,345 units (SEC Form 4)
- Chief Financial Officer Blumberg Scott sold $21,150 worth of shares (846 units at $25.00) as part of a pre-agreed trading plan and exercised 846 shares at a strike of $9.41 (SEC Form 4)
- Senior VP, Finance and PAO Foehr David sold $224,451 worth of shares (9,255 units at $24.25) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $4.70, decreasing direct ownership by 5% to 34,144 units (SEC Form 4)
- Chief Technology Officer Woo Raymond exercised 13,276 shares at a strike of $2.76 and sold $118,901 worth of shares (4,887 units at $24.33) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 203,118 units (SEC Form 4)
- President and CEO Chao Xingjuan sold $973,079 worth of shares (39,540 units at $24.61) as part of a pre-agreed trading plan and exercised 25,000 shares at a strike of $4.70, decreasing direct ownership by 2% to 767,191 units (SEC Form 4)
- Chief Financial Officer Blumberg Scott exercised 652 shares at a strike of $9.41 and sold $16,300 worth of shares (652 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Revenue Officer Manni Joseph S. sold $32,691 worth of shares (1,361 units at $24.02), decreasing direct ownership by 2% to 55,956 units (SEC Form 4) (tax liability)
- Senior VP, Finance and PAO Foehr David sold $44,425 worth of shares (1,852 units at $23.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 35,899 units (SEC Form 4) to cover withholding tax
Latest LIVN
- Barclays initiated coverage on LivaNova with a new price target
- LivaNova to Announce Third-Quarter 2026 Results
- SEC Form 4 filed by Chief Legal Officer Liddy Anne M.
- Director Bianchi Francesco sold $273,032 worth of Ordinary Shares (3,500 units at $78.01), decreasing direct ownership by 44% to 4,434 units (SEC Form 4)
- Director Story Brooke sold $187,270 worth of Ordinary Shares (2,300 units at $81.42), decreasing direct ownership by 23% to 7,488 units (SEC Form 4)
- LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
- Director Bianchi Francesco sold $131,538 worth of Ordinary Shares (1,650 units at $79.72), decreasing direct ownership by 17% to 7,934 units (SEC Form 4)
- SEC Form 3 filed by new insider Liddy Anne M.
- Chief Innovation Officer Tezel Ahmet exercised 12,692 units of Ordinary Shares at a strike of $52.68, returned $668,740 worth of Ordinary Shares to the company (8,589 units at $77.86), covered exercise/tax liability with 1,428 units of Ordinary Shares and sold $207,942 worth of Ordinary Shares (2,675 units at $77.74) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC